Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 351-360

  Pitari, Giovanni M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cyclic GMP; GCC agonists; Inflammatory bowel disease

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLIC GMP; CYCLOSPORIN; ESCHERICHIA COLI ENTEROTOXIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; GUANYLIN; INFLIXIMAB; LINACLOTIDE; MESALAZINE; PLACEBO; PLECANATIDE; SP 333; UNCLASSIFIED DRUG; UROGUANYLIN; ATRIAL NATRIURETIC FACTOR RECEPTOR; BACTERIAL TOXIN; ENTEROTOXIN; ENTEROTOXIN RECEPTOR; ESCHERICHIA COLI PROTEIN; HEAT STABLE TOXIN (E COLI); PEPTIDE; RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLON MUCOSA; COLON RESECTION; CONSTIPATION; DISULFIDE BOND; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; PROTEIN CLEAVAGE; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ULCERATIVE COLITIS; YERSINIA ENTEROCOLITICA; AGONISTS; COLITIS, ULCERATIVE; PHYSIOLOGY;

BACTERIAL TOXINS; COLITIS, ULCERATIVE; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; HUMANS; PEPTIDES; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 84876460077     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S32252     Document Type: Review

References (86)

1. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76(9):1323-1330.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12(38): 6102-6108.
3. Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA. 2001;285(5):643-647.
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-429.
5. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-434.
6. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(7):390-407.
7. Guerrant RL, Hughes JM, Chang B, Robertson DC, Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: studies of tissue specificity, potential receptors, and intermediates. J Infect Dis. 1980;142(2):220-228.
8. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept. 1999; 81(1-3):25-39.
9. Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther. 2007;9(4):403-410.
10. synergypharma.com [homepage on the Internet]. New York, NY: Synergy Pharmaceuticals, Inc. 2013. Available from: http://www.synergypharma.com. Accessed January 14, 2013.
11. Guarino A, Cohen MB, Giannella RA. Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr Res. 1987;21(6):551-555.
12. Waldman SA, O'Hanley P, Falkow S, Schoolnik G, Murad F. A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli. J Infect Dis. 1984;149(1):83-89.
13. Han X, Mann E, Gilbert S, et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One. 2011; 6(1):e16139.
14. Lin JE, Snook AE, Li P, et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One. 2012;7(2):e31686.
15. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63(5):941-948.
16. Schmitt CK, Meysick KC, O'Brien AD. Bacterial toxins: friends or foes? Emerg Infect Dis. 1999;5(2):224-234.
17. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52(3):375-414.
18. Mann EA, Jump ML, Wu J, Yee E, Giannella RA. Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion. Biochem Biophys Res Commun. 1997;239(2):463-466.
19. Schulz S, Lopez MJ, Kuhn M, Garbers DL. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest. 1997;100(6):1590-1595.
20. Pawlowski SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136(6):1874-1886.
21. Pitari GM, Zingman LV, Hodgson DM, et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci U S A. 2003;100(5):2695-2699.
22. Shailubhai K, Yu HH, Karunanandaa K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000;60(18):5151-5157.
23. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci U S A. 2001;98(14):7846-7851.
24. Currie MG, Fok KF, Kato J, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1992; 89(3):947-951.
25. Hamra FK, Forte LR, Eber SL, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1993;90(22):10464-10468.
26. Kita T, Smith CE, Fok KF, et al. Characterization of human uroguanylin: a member of the guanylin peptide family. Am J Physiol. 1994; 266(2 Pt 2):F342-F348.
27. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;99(2):76-82.
28. Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest. 1998; 78(1):101-108.
29. Hamra FK, Eber SL, Chin DT, Currie MG, Forte LR. Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc Natl Acad Sci U S A. 1997;94(6):2705-2710.
30. Cohen MB, Witte DP, Hawkins JA, Currie MG. Immunohistochemical localization of guanylin in the rat small intestine and colon. Biochem Biophys Res Commun. 1995;209(3):803-808.
31. Whitaker TL, Witte DP, Scott MC, Cohen MB. Uroguanylin and guanylin: distinct but overlapping patterns of messenger RNA expression in mouse intestine. Gastroenterology. 1997;113(3):1000-1006.
32. Scheving LA, Jin WH. Circadian regulation of uroguanylin and guanylin in the rat intestine. Am J Physiol. 1999;277(6 Pt 1): C1177-C1183.
33. Steinbrecher KA, Rudolph JA, Luo G, Cohen MB. Coordinate upregulation of guanylin and uroguanylin expression by hypertonicity in HT29-18-N2 cells. Am J Physiol. 2002;283(6):C1729-C1737.
34. Blanchard RK, Cousins RJ. Upregulation of rat intestinal uroguanylin mRNA by dietary zinc restriction. Am J Physiol. 1997;272(5 Pt 1): G972-G978.
35. Li Z, Knowles JW, Goyeau D, et al. Low salt intake down-regulates the guanylin signaling pathway in rat distal colon. Gastroenterology. 1996;111(6):1714-1721.
36. Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007;82(4):441-447.
37. Steinbrecher KA, Tuohy TM, Heppner Goss K, et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun. 2000;273(1):225-230.
38. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001; 61(7):3124-3130.
39. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.
40. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-1724.
41. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133(3):761-768.
42. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-1712.
43. Krause WJ, Cullingford GL, Freeman RH, et al. Distribution of heat-stable enterotoxin/guanylin receptors in the intestinal tract of man and other mammals. J Anat. 1994;184(Pt 2):407-417.
44. Krause WJ, Freeman RH, Eber SL, Hamra FK, Currie MG, Forte LR. Guanylyl cyclase receptors and guanylin-like peptides in reptilian intestine. Gen Comp Endocrinol. 1997;107(2):229-239.
45. Krause WJ, Freeman RH, Eber SL, et al. Distribution of Escherichia coli heat-stable enterotoxin/guanylin/uroguanylin receptors in the avian intestinal tract. Acta Anat. 1995;153(3):210-219.
46. Gong R, Ding C, Hu J, et al. Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science. 2011;333(6049):1642-1646.
47. Valentino MA, Lin JE, Snook AE, et al. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011;121(9): 3578-3588.
48. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci. 2009;14:1-18.
49. Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol. 1999;135:105-149.
50. Vaandrager AB, Bot AG, De Jonge HR. Guanosine 3′,5′- cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine. Gastroenterology. 1997;112(2):437-443.
51. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, Gardner P. Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J. 1994;13(5):1065-1072.
52. Vaandrager AB, Bot AG, Ruth P, Pfeifer A, Hofmann F, De Jonge HR. Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon. Gastroenterology. 2000;118(1):108-114.
53. Zuzga DS, Pelta-Heller J, Li P, Bombonati A, Waldman SA, Pitari GM. Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. Int J Cancer. 2012;130(11):2539-2548.
54. Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther. 2002;1(10):803-809.
55. Benz PM, Blume C, Seifert S, et al. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci. 2009; 122(Pt 21):3954-3965.
56. Lindsay SL, Ramsey S, Aitchison M, Renne T, Evans TJ. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J Cell Sci. 2007;120(Pt 17): 3011-3021.
57. Biel M, Zong X, Ludwig A, Sautter A, Hofmann F. Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol. 1999;135:151-171.
58. Pitari GM, Lin JE, Shah FJ, et al. Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis. 2008;29(8):1601-1607.
59. Pitari GM, Baksh RI, Harris DM, Li P, Kazerounian S, Waldman SA. Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 2005;65(23):11129-11135.
60. Moens E, Veldhoen M. Epithelial barrier biology: good fences make good neighbours. Immunology. 2012;135(1):1-8.
61. Potten CS, Booth C, Pritchard DM. The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol. 1997;78(4):219-243.
62. Sanders DS. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol. 2005;58(6): 568-572.
63. Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am J Pathol. 2002; 161(6):2169-2178.
64. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic regulation of the crypt-to-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol. 2007;171(6):1847-1858.
65. Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133(2):599-607.
66. Lin JE, Li P, Snook AE, et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2010;138(1):241-254.
67. Heazlewood CK, Cook MC, Eri R, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 2008; 5(3):e54.
68. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12(5): 319-330.
69. Bachmann O, Seidler U. News from the end of the gut how the highly segmental pattern of colonic HCO(3)(-) transport relates to absorptive function and mucosal integrity. Biol Pharm Bull. 2011;34(6): 794-802.
70. Sandle GI, Higgs N, Crowe P, Marsh MN, Venkatesan S, Peters TJ. Cellular basis for defective electrolyte transport in inflamed human colon. Gastroenterology. 1990;99(1):97-105.
71. Wojciak-Stothard B, Torondel B, Zhao L, Renne T, Leiper JM. Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol Biol Cell. 2009;20(1):33-42.
72. Schlegel N, Waschke J. Vasodilator-stimulated phosphoprotein: crucial for activation of Rac1 in endothelial barrier maintenance. Cardiovasc Res. 2010;87(1):1-3.
73. Ivanov AI, McCall IC, Parkos CA, Nusrat A. Role for actin filament turnover and a myosin II motor in cytoskeleton-driven disassembly of the epithelial apical junctional complex. Mol Biol Cell. 2004;15(6): 2639-2651.
74. Sturm A, Dignass AU. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol. 2008;14(3): 348-353.
75. Keyashian K, Annunziata ML, Sakuraba A, Hanauer S. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012;8(4):303-305.
76. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17(27):3204-3212.
77. Jenkins HR. Inflammatory bowel disease. Arch Dis Child. 2001;85(5): 435-437.
78. Loftus EV Jr, Delgado DJ, Friedman HS, Sandborn WJ. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103(7):1737-1745.
79. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575-1580.
80. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799-809.
81. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-175.
82. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13(7):807-821.
83. Fiskerstrand T, Arshad N, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. N Engl J Med. 2012;366(17):1586-1595.
84. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99(9): 1774-1778.
85. Cuppoletti J, Blikslager AT, Chakrabarti J, Nighot PK, Malinowska DH. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol. 2012;12(1):3.
86. Steinbrecher KA, Harmel-Laws E, Garin-Laflam MP, et al. Murine guanylate cyclase C regulates colonic injury and inflammation. J Immunol. 2011;186(12):7205-7214